Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bicara Therapeutics Inc. ( (BCAX) ) has issued an announcement.
On February 24, 2026, Bicara Therapeutics entered an underwriting agreement with a syndicate led by Morgan Stanley, TD Securities and BofA Securities to sell 7,175,000 common shares and pre-funded warrants for 2,200,000 additional shares at public offering prices of $16.00 and $15.9999, respectively. The underwriters fully exercised a 30-day option to buy 1,406,250 extra shares on February 25, 2026, and the offering closed on February 26, 2026, providing Bicara with approximately $161.8 million in net proceeds, which will fund regulatory and commercial preparations, expanded clinical development, manufacturing, and broader indication-finding work for its lead cancer therapy ficerafusp alfa, as well as general corporate purposes.
The pre-funded warrants are immediately exercisable at a nominal $0.0001 per share or via cashless exercise, but are subject to ownership caps that limit any holder and affiliates to under 9.99% of outstanding shares unless adjusted with prior notice. Bicara’s choice not to list the pre-funded warrants and the use of an effective shelf registration supports a streamlined capital-raising strategy while mitigating ownership concentration, reinforcing the company’s financial position as it advances late-stage development and potential commercialization of ficerafusp alfa.
The most recent analyst rating on (BCAX) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Bicara Therapeutics Inc. stock, see the BCAX Stock Forecast page.
Spark’s Take on BCAX Stock
According to Spark, TipRanks’ AI Analyst, BCAX is a Neutral.
Overall score reflects a strong solvency position and positive clinical/program milestones, partially offset by the lack of revenue and rapidly increasing losses/free-cash-flow burn. Technicals are mildly weak/neutral and valuation metrics offer limited support due to ongoing unprofitability.
To see Spark’s full report on BCAX stock, click here.
More about Bicara Therapeutics Inc.
Bicara Therapeutics Inc. is a biopharmaceutical company focused on developing and commercializing ficerafusp alfa, an oncology therapy targeting first-line human papillomavirus-negative recurrent or metastatic head and neck squamous cell carcinoma. The company is building out medical, commercial, and manufacturing infrastructure in preparation for potential U.S. regulatory filings and a commercial launch, as well as exploring future indication expansions for its lead asset.
Average Trading Volume: 525,187
Technical Sentiment Signal: Buy
Current Market Cap: $889.7M
For detailed information about BCAX stock, go to TipRanks’ Stock Analysis page.